Cargando…

Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis

BACKGROUND: Elevated interleukin (IL)-6-levels have been described in familial variant transthyretin amyloidosis (ATTRv) associated polyneuropathy and heart failure. However, IL-6 in cardiac ATTR amyloidosis (ATTR-CM) and its prognostic value have not been investigated yet. AIM: We aim to study the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hein, Selina J, Knoll, Maximilian, Aus dem Siepen, Fabian, Furkel, Jennifer, Schoenland, Stefan, Hegenbart, Ute, Katus, Hugo A, Kristen, Arnt V, Konstandin, Mathias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Prospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988596/ https://www.ncbi.nlm.nih.gov/pubmed/33791079 http://dx.doi.org/10.4330/wjc.v13.i3.55

Ejemplares similares

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
por: Siepen, Fabian aus dem, et al.
Publicado: (2015)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis
por: Hoerbrand, Isabel A., et al.
Publicado: (2022)

T1 mapping: useful for treatment monitoring in patients with senile systemic amyloidosis?
por: dem Siepen, Fabian aus, et al.
Publicado: (2014)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Non-invasive risk stratification of patients with TTR amyloidosis
por: Scherer, Katrin A, et al.
Publicado: (2013)

Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms
por: Korosoglou, Grigorios, et al.
Publicado: (2021)

Cardiac magnetic resonance strain imaging in systemic light chain amyloidosis
por: Andre, Florian, et al.
Publicado: (2014)

Comparison of late gadolinium enhancement patterns in different forms of cardiac amyloidosis
por: Kammerer, Rebekka, et al.
Publicado: (2013)

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
por: Ochs, Marco M., et al.
Publicado: (2017)

Thickness of the midventricular left ventricular wall is predictive of survival in different forms of cardiac amyloidosis
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Non-invasive measurement of myocardial extracellular volume using T1 mapping as a novel biomarker of diffuse fibrosis in dilated cardiomyopathy
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

C-MORE: A high-content single-cell morphology recognition methodology for liquid biopsies toward personalized cardiovascular medicine
por: Furkel, Jennifer, et al.
Publicado: (2021)

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
por: Kristen, Arnt V., et al.
Publicado: (2012)

PW03-029 – Risk factors for AA-type amyloidosis in Germany
por: Blank, N, et al.
Publicado: (2013)

Assessment of myocardial strain in patients with myocarditis by cardiac magnetic resonance imaging
por: Andre, Florian, et al.
Publicado: (2014)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Diffuse myocardial fibrosis in early forms of dilated cardiomyopathy: insights from T1 mapping cardiovascular magnetic resonance
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Right ventricular function in dilated cardiomyopathy: relation to location of focal myocardial fibrosis
por: Abdelrazek, Mohamed A, et al.
Publicado: (2013)

Extracellular volume assessed by CMR T1-mapping correlates with histologically determined amount of diffuse fibrosis in DCM
por: aus dem Siepen, Fabian, et al.
Publicado: (2014)

MRI detected mass decrease in patients with amyloidosis after treatment with green tea: a one year follow-up study
por: Buss, Sebastian, et al.
Publicado: (2012)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2014)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)
por: Yilmaz, A., et al.
Publicado: (2021)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
por: Zou, Huizhen, et al.
Publicado: (2023)

Variability of cardiovascular magnetic resonance (CMR) T1 mapping parameters in healthy volunteers during long-term follow-up
por: aus dem Siepen, Fabian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nasc8c3j19ba5gtn4acp1tsdk5